Search research articles
Contact Us
Filters
Showing results (131-140 of 273) with videos related to
Page
of 28
Sort By:
JTO Clinical and Research Reports
|
March 9, 2026
Acquired <i>ERBB2</i> Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report
David John McMahon, Alexius John, Foteini Kalofonou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 19, 2011
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib
Sanjay Popat, Alexandra Vieira de Araújo, Toon Min, et al.
The Breast Journal
|
March 4, 2008
Time trends in the outcome of elderly patients with breast cancer
Sarah Hughes, Yolanda Barbachano, Sue Ashley, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 22, 2023
Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
Mo Yang, Helene Vioix, Emma S Hook, et al.
JTO Clinical and Research Reports
|
December 6, 2021
Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations
Sebastian Curcean, Lin Cheng, Simona Picchia, et al.
Cancer Chemotherapy and Pharmacology
|
December 27, 2015
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
Rajiv Kumar, Shir Kiong Lu, Anna Minchom, et al.
Current Medical Research and Opinion
|
July 11, 2022
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L
Karen L Reckamp, Huamao M Lin, Holly Cranmer, et al.
Clinical Lung Cancer
|
April 19, 2023
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Makoto Nishio, Luis Paz-Ares, Martin Reck, et al.
BMC Cancer
|
September 18, 2014
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
Mark Linch, Spyridon Gennatas, Stanislav Kazikin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 7, 2006
Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence
Richard A Hubner, Kenneth R Muir, Jo-Fen Liu, et al.
Page
of 28
Search research articles
Search
Showing results (131-140 of 273) with videos related to
Sort By:
Page
of 28
JTO Clinical and Research Reports
|
March 9, 2026
Acquired <i>ERBB2</i> Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report
David John McMahon, Alexius John, Foteini Kalofonou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 19, 2011
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib
Sanjay Popat, Alexandra Vieira de Araújo, Toon Min, et al.
The Breast Journal
|
March 4, 2008
Time trends in the outcome of elderly patients with breast cancer
Sarah Hughes, Yolanda Barbachano, Sue Ashley, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 22, 2023
Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
Mo Yang, Helene Vioix, Emma S Hook, et al.
JTO Clinical and Research Reports
|
December 6, 2021
Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations
Sebastian Curcean, Lin Cheng, Simona Picchia, et al.
Cancer Chemotherapy and Pharmacology
|
December 27, 2015
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients
Rajiv Kumar, Shir Kiong Lu, Anna Minchom, et al.
Current Medical Research and Opinion
|
July 11, 2022
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L
Karen L Reckamp, Huamao M Lin, Holly Cranmer, et al.
Clinical Lung Cancer
|
April 19, 2023
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Makoto Nishio, Luis Paz-Ares, Martin Reck, et al.
BMC Cancer
|
September 18, 2014
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
Mark Linch, Spyridon Gennatas, Stanislav Kazikin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 7, 2006
Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence
Richard A Hubner, Kenneth R Muir, Jo-Fen Liu, et al.
Page
of 28